On September 14, 2023, Model Medicines presented our industry-leading AI drug discovery platform GALILEO and lead pan-antiviral asset MDL-001 to experts from BARDA and other government agencies.

The BARDA TechWatch program enables companies to gain valuable feedback on how their technologies and pipeline could address critical capability gaps in medical countermeasures.

Our discussion focused on:

• Model's threat-agnostic approach to discovering optimized therapies

• The ability of our platform to traverse vast chemical space

• MDL-001's potential as a broad spectrum antiviral

• Partnership opportunities to tackle pressing public health priorities

• We appreciated the collaborative dialogue around developing flexible solutions aligned with BARDA's mission of preparedness.

Model Medicines remains committed to working with key stakeholders across industry and government to rapidly respond to health security threats with breakthrough medicines designed for patients.